节点文献

洛伐他汀缓释片在人体内的药代动力学研究

Pharmacokinetic studies on the extended-release tablets of lovastatin in human volunteers

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 孙建国; 翁合霞; 王广基; 李鹏; 李昊;

【Author】 SUN Jian-guo~1,WENG He-xia~2,WANG Guang-ji~1,LI Peng~1,LI Hao~1~1Key Laboratory of Drug Metabolism and Pharmacokinetics,China Pharmaceutical University,Nanjing 210038;~2Nanyang Medical College,Nanyang 473058,China

【机构】 中国药科大学药物代谢动力学重点实验室; 南阳医学高等专科学校; 中国药科大学药物代谢动力学重点实验室 南京210038; 南阳473058; 南京210038;

【摘要】 目的:研究洛伐他汀缓释片在人体内单次和多次口服给药后的药代动力学过程。方法:采用LC-MS/MS方法测定人血浆中洛伐他汀的浓度。采用正离子方式检测;扫描方式为选择离子反应监测(SRM)。20名男性健康受试者随机双交叉单次(40 mg)或多次(20 mg×6)口服洛伐他汀缓释片和普通制剂海立片,并于相应的时间点取血测定血浆中的药物浓度。结果:所建立的LC-MS/MS方法的线性范围为0.05~10.0 ng/mL,最低检测浓度为0.05 ng/mL。以海立片为参比对照,用面积法估算的单次和多次给药后洛伐他汀缓释片中洛伐他汀的相对生物利用度分别为(148.5±43.1)%和(140.7±32.8)%。估算单次给药后海立片和洛伐他汀缓释片的人体内洛伐他汀的MRT为(14.61±7.27)h和(29.72±17.22)h;tmax为(4.2±2.1)h和(12.3±7.5)h;cmax为(1.98±1.01)ng/mL和(1.64±0.62)ng/mL;t1/2为(12.16±5.18)h和(18.17±10.78)h。海立片和洛伐他汀缓释片的稳态药物浓度分别为(0.57±0.27)ng/mL和(0.80±0.43)ng/mL,波动度分别为(2.64±1.10)和(0.97±0.36)。结论:单剂量给药后洛伐他汀缓释片与海立片相比,产生的cmax比较平稳,tmax延迟,两种给药方式洛伐他汀缓释片的吸收程度均高于普通制剂。

【Abstract】 Aim:To study the pharmacokinetics of lovastatin after a single and multiple oral doses of extended-release lovastatin tablets in 20 healthy Chinese volunteers by LC-MS/MS.Methods:Lovasatatin is quantitatively determined by LC-MS/MS using positive ion detection with selected reaction monitoring(SRM).Extended-release or convention tablets were given to 20 healthy volunteers single dose(40 mg)or multiple doses(20 mg×6) in a two-way crossover design.Blood was drawn at different intervals after treatment.Results:The LC-MS/MS method was proved to be linear over the range of 0.05~10.0 ng/mL of lovastatin with limit of quantitation of 0.05 ng/mL.Compared with conventional tablet,the relative bioavailability of lovastatin ER is about(148.5±43.1)% and(140.7±32.8)% after single or multiple doses,respectively.The pharmacokinetic parameters of lovastatin after single dose were as follows: MRT were(14.61±7.27) h and(29.72±17.22)h,tmax were(4.2±2.1)h and(12.3±7.5) h,cmax were(1.98±1.01)ng/mL and(1.64±0.62) ng/mL,and t1/2 were(12.16±5.18)h and(18.17±10.78)h for conventional tablet and lovastatin ER,respectively.The mean steady state concentrations(css) of lovastatin after six consecutive days treatment with the two formulations were(0.57±0.27) and(0.80±0.43) ng/mL with fluctuate degree(DF) of 2.64±1.10 and 0.97±0.36,respectively.Conclusions:Compared with the conventional tablet,the lovastatin ER shown a delayed tmax,lower cmax and higher bioavailability.

【基金】 国家高技术研究发展计划(“八六三”计划)资助项目(No.2003AA2Z347A,2005AA2Z3C70)~~
  • 【文献出处】 中国药科大学学报 ,Journal of China Pharmaceutical University , 编辑部邮箱 ,2006年05期
  • 【分类号】R96
  • 【下载频次】482
节点文献中: 

本文链接的文献网络图示:

本文的引文网络